Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

23
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence...
23
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

26
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...
26
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

27
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...
27
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

26
Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
26

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Venous Sinus Stenting Outcomes in Patients with Papilledema from Secondary Causes of Elevated Intracranial Pressure.

Neuro-ophthalmology (Aeolus Press)·2026
Same author

Embryologic and Fetal Development of the Human Lacrimal System.

Ophthalmic plastic and reconstructive surgery·2026
Same author

Teaching NeuroImages: Topless Optic Disc or Superior Segmental Optic Nerve Hypoplasia.

Neurology·2026
Same author

Jugular Bulb Arteriovenous Fistula Induced Papilledema.

Ophthalmology·2026
Same author

Too much of a good thing.

Survey of ophthalmology·2026
Same author

Epidemiology of Adult-Onset Nystagmus and Saccadic Intrusions of Central Etiologies: A Population-Based Study in Olmsted County.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society·2025

Related Experiment Video

Updated: Apr 29, 2026

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

1.1K

Thyroid eye disease: therapy in the active phase.

M Tariq Bhatti1, Jonathan J Dutton

  • 1Departments of Ophthalmology and Neurology (MTB), Duke Eye Center and Duke University Medical Center, Durham, North Carolina; and Department of Ophthalmology (JJD), University of North Carolina, Chapel Hill, North Carolina.

Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society
|May 14, 2014
PubMed
Summary
This summary is machine-generated.

Managing active thyroid eye disease (TED) requires a team approach. Systemic corticosteroids are first-line for moderate-to-severe TED, often needing multimodal therapy for optimal outcomes.

More Related Videos

Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction
05:00

Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction

Published on: April 1, 2019

14.8K

Related Experiment Videos

Last Updated: Apr 29, 2026

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

1.1K
Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction
05:00

Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction

Published on: April 1, 2019

14.8K

Area of Science:

  • Ophthalmology
  • Endocrinology
  • Immunology

Background:

  • Active thyroid eye disease (TED) presents complex management challenges due to its heterogeneity and unpredictability.
  • A multidisciplinary team approach is essential for addressing the pathogenic complexity and ocular morbidity of TED.

Purpose of the Study:

  • To review current management strategies for active thyroid eye disease (TED).
  • To evaluate the efficacy of established and emerging treatments for TED.
  • To highlight the need for standardized outcome measures in TED clinical trials.

Main Methods:

  • A comprehensive literature search was conducted using PubMed, covering terms related to Graves' disease and TED treatments up to December 2013.
  • Included were manuscripts in English, supplemented by references from retrieved articles and textbooks.

Main Results:

  • Corticosteroids, orbital radiotherapy (ORT), and orbital decompression have been primary treatments for active TED for over five decades.
  • Limited high-quality randomized controlled studies exist, with inconsistencies in design and outcome measures hindering comparisons.
  • Emerging immunosuppressive and immunomodulating agents show anecdotal promise for improved efficacy.

Conclusions:

  • Patient assessment of TED activity and severity is crucial for guiding treatment decisions.
  • Risk factor modification, including smoking cessation and achieving euthyroid status, is fundamental.
  • Systemic corticosteroids are the first-line treatment for moderate-to-severe TED and dysthyroid optic neuropathy, often requiring a multimodal approach with ORT or orbital decompression.
  • Development of novel targeted immunotherapies and standardized outcome measures are needed to advance evidence-based TED management.